 Aethlon Medical, Inc. Nasdaq:AEMD Aethlon or the Company, a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, today announced the completion of its previously announced registered direct offering of 1,885,378 shares of its common stock, at a purchase price per share of 2.00, priced at-the-market under Nasdaq rules. Additionally, Aethlon issued to the purchasers unregistered warrants to purchase up to 942,689 shares of common stock. The warrants have an exercise price of 2.75 per share of common stock, are exercisable immediately and will expire five and one-half years from the issuance date. 